Instituto Finlay de Vacunas (IFV) is a Cuban vaccine research and development organization dedicated to protecting health through science and innovation. Its work spans the full vaccine lifecycle, including research, development, production, clinical evaluation, marketing, and post-market monitoring. The institute applies high-technology platforms and approaches such as glycoconjugate, synthetic, combined, and therapeutic vaccines, with a focus on infectious diseases and pressing health needs in Cuba and worldwide.

IFV’s portfolio includes vaccines and vaccine candidates, as well as projects involving active pharmaceutical ingredients and clinical evaluation. Its products include VA-MENGOC-BC, developed to address meningococcal disease; a trivalent inactivated vaccine against leptospirosis; and Quimi-Vio, a pneumococcal conjugate vaccine covering seven serotypes. The institute also conducts clinical studies, impact assessments, and pharmacovigilance, and collaborates with national and international partners. Its capabilities support vaccine research, production, and evaluation, while its stated practices emphasize quality, responsible operations, and environmental care. IFV also provides scientific information and educational resources for health professionals, researchers, students, and organizations involved in biological products.